# A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia

> **NCT01942161** · PHASE2,PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 106 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Aripiprazole Low (2 mg/day)
- **DRUG:** Aripiprazole Mid (6 - 12 mg/day)
- **DRUG:** Aripiprazole High (24 - 30 mg/day)

## Key facts

- **NCT ID:** NCT01942161
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2017-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01942161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01942161, "A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01942161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*